Prevention of N-Methylnitrosourea-induced Colon Tumorigenesis by Ursodeoxycholic Acid in F344 Rats

Tomio Narisawa,1, 4 Yoko Fukaura,1 Kunihiko Terada2 and Hideaki Sekiguchi3
1 Akita University College of Allied Medical Sciences, 2 Department of Biochemistry, Akita University School of Medicine, Hondo 1-1-1, Akita 010-8543 and 3 Ashikaga Plant, Tokyo Tanabe Co., Ltd., Kubota-cho 588-3, Ashikaga, Tochigi 326-0324

Bile acids are known to promote colon carcinogenesis. However, there is one study showing that ursodeoxycholic acid (UDCA) supplemented in the diet at the concentration of 0.4% prevented azoxymethane-induced rat colon tumorigenesis. The aim of our study was to explore the inhibitory effect of a much smaller dose of UDCA on colon carcinogenesis in rats. One hundred 7-week-old F344 rats were given 2 mg of N-methylnitrosourea 3 times a week for 3 weeks by intrarectal instillation, and were fed a 0% (control), 0.4% or 0.08% UDCA-supplemented diet for the next 27 weeks. All the rats were killed and examined for tumor development at week 30. The tumor incidence and number were significantly lower and smaller, respectively, in the UDCA-fed rats than in the control rats: 40% and 36% vs. 68%; 0.5±0.1 (mean±SEM) and 0.4±0.1 vs. 1.0±0.2. All the tumors were located in the distal half of the colon and were plaque-shaped or polypoid, being well-differentiated adenocarcinomas restricted to the mucosa or submucosa. Bile acids in the feces and the blood obtained at weeks 20 and 30, respectively, were analyzed by HPLC. A significant increase of UDCA was confirmed in both the feces and the blood of the UDCA-fed rats compared with the control rats. The results suggest that the continuous feeding of a small dose of UDCA may prevent colon carcinogenesis.

Key words: Colon cancer — Cancer prevention — Ursodeoxycholic acid

Epidemiological studies have indicated that a diet rich in fat is associated with an increased risk of colon cancer.1 According to various lines of evidence, bile acids, which are required for dietary fat metabolism, may play an important role in colon carcinogenesis.2 In humans and rodents, a diet with a high content of fat causes a physiological increase of bile acids in the bile and of their excretion into feces. Studies with rats have shown that bile acids, particularly secondary bile acids (deoxycholic acid and lithocholic acid), contribute to the promotion of colon carcinogenesis.3–6 In those studies, bile acids were applied directly on the colonic mucosa via the rectum or indirectly by adding them to feed. However, Czygan et al. reported that among rats administered 1,2-dimethylhydrazine to induce colon cancer, those fed a diet supplemented with 1% ursodeoxycholic acid (UDCA) showed no increased development of colon tumors, compared to control rats fed a standard diet, while feeding of other bile acids increased the lesions.7 Our preliminary short-term (5 weeks) experiment showed that the number of N-methylnitrosourea (MNU)-induced aberrant crypt foci in the rat colon, while feeding of other bile acids increased the lesions.8 Our preliminary short-term (5 weeks) experiment showed that the number of N-methylnitrosourea (MNU)-induced aberrant crypt foci in the colon of rats fed diets supplemented with 0.4%, 0.08% or 0.016% UDCA was 76%, 77% and 92% of that in the control rats without UDCA feeding, respectively (unpublished data).

The present study was conducted to examine the inhibitory effect of UDCA administered as a supplement in the diet at the levels of 0.4% and 0.08% on MNU-induced colon tumorigenesis in rats. UDCA inhibited colon tumor development at both dose levels. The results are different from those reported by Earnest et al.4 Serum and fecal bile acids were also measured to analyze the mechanism of the inhibitory activity of UDCA.

MATERIALS AND METHODS

Female F344/Nrslc rats (Shizuoka Laboratory Animal Center, Hamamatsu), 7 weeks of age at the start of the experiment, were used. They were housed, 5 rats per cage, in plastic cages with sterilized wood-chip bedding in a specific-pathogen-free room under constant environmental conditions with a 12 h light and dark cycle, a tempera-

4 To whom correspondence and reprints requests should be addressed.
ture of 22°C and a relative humidity of 50%. They had free access to a standard pelleted chow CE-2 (CLEA Co., Tokyo) and drinking water. The body weight and food intake were measured once a week. Two test diets containing UDCA (purity 99.5%; Tokyo Tanabe Co., Tokyo) in CE-2 chow at the level of 0% or 0.08% (w/w) were prepared at CLEA Co. The concentrations of UDCA in these diets were confirmed by HPLC.

One hundred rats were given 0.5 ml of 0.4% aqueous solution of MNU (Nacalai Tesque, Kyoto) 3 times a week for 3 weeks by intrarectal instillation. The solution was prepared immediately before use. A metal feeding tube 8 cm long was inserted two-thirds into the colon lumen through the anal orifice, and the solution was injected.13) The solution filled the distal half of the colon where the tumors develop. After completion of treatment with the carcinogen, the rats were divided into 3 groups fed diet supplemented with 0%, 0.4% or 0.08% UDCA (the control, UDCA (h) and UDCA (l) groups, respectively) for 27 weeks. The feces were collected for 3 days at week 20, stored at −80°C and analyzed for bile acid content.

At the end of week 30, all the rats were killed by exsanguination from the abdominal aorta after laparotomy under intraperitoneal pentobarbital anesthesia (40 mg/kg body weight). The blood was centrifuged, and the serum was collected and stored at −20°C for 1 h, then centrifuged at 1,800 g for 10 min, and the supernatant was transferred into another test tube. The residue was further extracted twice with 5 ml of ethanol. One milliliter of the serum was extracted with the same volume of ethanol, then evaporated to dryness. The extracts from the feces and the serum were redissolved in 2 ml of methanol and centrifuged at 1,800 g for 10 min. The supernatant (100 µl) was mixed with 23-nordeoxycholic acid (100 µl of 60 µmol/liter methanolic solution) as an internal standard, and 20 µl of this solution was used for bile acid analysis by HPLC.

The statistical significance of differences was tested by use of the χ² test and Student’s t test. The criterion of significance was a P value of <0.05.

RESULTS

The body weight gain was similar in all groups. The mean weight was 115 g at week 1, and 214–216 g at week 30 in all groups. The values of mean food intake were 9.6, 9.5 and 9.9 g/day/rat in the control, UDCA (h) and UDCA (l) groups, respectively. Thus, the mean amount of ingested UDCA was computed to be 200 mg/kg body weight/day in the UDCA (h) group and 41 mg/kg body weight/day in the UDCA (l) group.

Data regarding the development of colon tumors are summarized in Table I. The incidence and number of tumors were significantly lower in the UDCA (h) and UDCA (l) groups than in the control group. However, the number of tumors per tumor-bearing rat was almost the same in all the groups. The tumors were located diffusely in the distal half of the colon, and were plaque-shaped or polypoid. Histologically, all the tumors were well-differentiated adenocarcinomas. Most of them were small, less than 10 mm in diameter, and restricted to the mucosa or submucosa. No metastases to lymph nodes or other organs were observed because the experiment was terminated after only 30 weeks. No distinct differences among the groups were observed in the location, shape, size, depth

| Treatment groups | Number of rats examined | Number of rats with tumors | Number of tumors/rat | Number of tumors/tumor-bearing rat |
|------------------|-------------------------|---------------------------|---------------------|-----------------------------------|
| Control          | 25                      | 17 (68%)                  | 1.0±0.2             | 1.5±0.1                           |
| UDCA (h)         | 50                      | 20 (40%)                  | 0.5±0.1             | 1.3±0.1                           |
| UDCA (l)         | 25                      | 9 (36%)                   | 0.4±0.1             | 1.2±0.1                           |

a) All rats were given an intrarectal dose of 2 mg of MNU 3 times a week for 3 weeks, and then fed a diet containing 0% (control group), 0.4% (UDCA (h) group) or 0.08% (UDCA (l) group) UDCA for 27 weeks. All rats were killed at the end of week 30.
b) Mean±SEM.
c) Significantly different from control group: P<0.05 or 0.01.
Ursodeoxycholate Prevents Rat Colon Tumors

There were no other pathologic findings in the gastrointestinal tract or other organs in any of the groups. Thus, the data clearly demonstrate that both high and low doses of UDCA inhibited the development of MNU-induced colon tumors.

The mean weight of feces excreted at week 20 was 2.8 g/day/rat (1.7 or 1.8 g dry weight/day/rat) in all the groups. The results of fecal bile acids analysis are summarized in Table II. The amounts of individual and total bile acids were significantly larger in the UDCA groups than in the control group. It was noted that excessive amounts of ω-muricholic acid, hyodeoxycholic acid and lithocholic acid, which are derived from UDCA in the colon, were excreted in the feces of rats in the UDCA groups. The serum bile acids showed significant increases of UDCA and lithocholic acid in the UDCA groups and of total bile acids in the UDCA (h) group, compared with the control group (Table III). In particular, an excess amount of UDCA was noted. The level of cholic acid, a primary bile acid, was significantly lower in the UDCA (h) group than in the control group.

### DISCUSSION

The present study demonstrated that UDCA administered as a supplement in the diet at concentrations of 0.4% and 0.08% inhibited the development of MNU-induced colon tumors in rats. The inhibitory effect was similar at both dose levels. These results were in agreement with those of our preliminary study, in which formation of MNU-induced colonic aberrant crypt foci was suppressed in rats fed the same diets for 5 weeks. The effect of UDCA on AOM-induced colonic aberrant crypt foci in rats was also confirmed in a recent study. Earnest et al. reported that the development of AOM-induced colon tumors was inhibited in rats fed a diet containing 0.4% UDCA, but not in those fed a diet containing 0.2% UDCA. The discrepancy between their results and ours seems likely to be due to the difference in the carcinogens used, i.e., subcutaneous AOM and intrarectal MNU. Our results constitute evidence of the inhibitory effect of UDCA at the low dose level of 41 mg/kg body weight/day on colon carcinogenesis in an animal model.

### Table II. Analysis of Bile Acids Excreted into Feces from F344 Rats Fed a Diet Containing Ursodeoxycholic Acid

| Treatment groups | α- & β-MCA | ω-MCA | HyoDCA | DCA | 12-Keto-LCA | UDCA | LCA | Total bile acids |
|------------------|------------|-------|--------|-----|-------------|------|-----|-----------------|
| Control (n=15)   | 0.08±0.02c | 0.28±0.03 | 0.55±0.08 | 0.26±0.06 | 0.45±0.07 | 0.06±0.004 | 0.21±0.01 | 1.86±0.26 |
| UDCA (h) (n=15) | 0.64±0.07* | 1.71±0.12* | 1.27±0.17* | 0.56±0.02* | 0.80±0.01* | 0.48±0.05* | 6.98±0.18* | 12.43±0.44* |
| UDCA (l) (n=15) | 0.30±0.06* | 0.64±0.16 | 1.13±0.18* | 0.51±0.03* | 0.83±0.04* | 0.15±0.01* | 1.57±0.06* | 5.13±0.05* |

_c) See text or Table I.
_b) Mean±SEM, µmol/g dry feces.
* Significantly different from control group: P<0.05 or more.
MCA: muricholic acid, DCA: deoxycholic acid, LCA: lithocholic acid, UDCA: ursodeoxycholic acid.

### Table III. Analysis of Bile Acids in Serum of F344 Rats Fed a Diet Containing Ursodeoxycholic Acid

| Treatment groups | α- & β-MCA | CA | CDCA | HyoDCA | DCA | UDCA | LCA | Total |
|------------------|------------|----|------|--------|-----|------|-----|-------|
| Control (n=8)    | 1.7±0.3c  | 3.3±0.5 | 1.8±0.5 | 1.1±0.2 | 0.1±0.05 | NDc | ND  | 8.0±1.1 |
| UDCA (h) (n=8)  | 3.5±0.8  | 0.6±0.1* | 3.7±0.7 | 0.7±0.2 | 0.2±0.1 | 6.3±0.8* | 0.7±0.1* | 15.3±2.3* |
| UDCA (l) (n=8)  | 2.9±0.6  | 3.4±0.7 | 2.4±0.6 | 1.4±0.3 | 0.1±0.04 | 2.4±0.5* | 0.2±0.1* | 12.8±2.7 |

_a) See text or Table I.
_b) Mean±SEM, nmol/ml.
_c) Not detected.
* Significantly different from the control group: P<0.05 or more.
MCA: muricholic acid, CA: cholic acid, CDCA: chenodeoxycholic acid, DCA: deoxycholic acid, UDCA: ursodeoxycholic acid, LCA: lithocholic acid.
The present study confirmed that orally administered UDCA results in a marked increase of UDCA and lithocholic acid, which was derived from UDCA in the colon, as well as total bile acids in the feces and in the blood. UDCA was shown to enhance apoptosis of human colon cancer cells in an in vitro study, while lithocholic acid did not show such effect. On the other hand, deoxycholic acid had no effect on apoptosis of colon cancer cells at physiological low doses, but induced apoptosis as well as cytotoxicity at very high doses. Failure of damaged cells to undergo apoptosis is now believed to be responsible for the growth of neoplasms, including colon tumors. UDCA suppressed AOM-induced activation of protein kinase C, an intermediate biomarker of tumor promotion, in the colon mucosa of rats. We observed in rats that UDCA did not enhance colon mucosal ornithine decarboxylase activity as a biomarker of tumor promotion, while deoxycholic and chenodeoxycholic acids significantly enhanced it. Furthermore, UDCA was shown to inhibit angiogenesis in chick embryo chorioallantoic membrane. It is established that secondary bile acids, deoxycholic acid and lithocholic acid, enhance colonic cell proliferation and colon carcinogenesis. Those studies suggest that UDCA has a specific biological activity, different from other bile acids, in suppressing the promotion and/or progression phases of colon carcinogenesis. However, we have no data on colonic cell proliferation and apoptosis in the present study with an animal model. Further studies are necessary to clarify the possible mechanism of the chemopreventive action of UDCA on colon carcinogenesis.

In conclusion, the continuous feeding of a diet containing a low dose of UDCA (0.08%) inhibited MNU-induced colon cancer development in rats to the same extent as did that of a diet containing a high dose of UDCA (0.4%). It is expected that much smaller doses of UDCA might prevent colon carcinogenesis via an alteration in bile acid composition in the blood and feces, influencing the interaction with colonic cells.

ACKNOWLEDGMENTS

The authors thank Mr. K. Toita for his excellent technical assistance.

(Received May 28, 1998/Revised July 29, 1998/Accepted August 4, 1998)

REFERENCES

1) Potter, J. D., Slattery, M. L., Bostick, R. M. and Gapstur, S. M. Colon cancer: a review of the epidemiology. Epidemiol. Rev., 15, 499–545 (1993).
2) Weisburger, J. H. Causes, relevant mechanisms, and prevention of large bowel cancer. Semin. Oncol., 18, 316–336 (1991).
3) Narisawa, T., Magadia, N. E., Weisburger, J. H. and Wynder, E. L. Promoting effect of bile acids on colon carcinogenesis after intrarectal instillation of N-methyl-N-nitro-N-nitrosoguaidine in rats. J. Natl. Cancer Inst., 53, 1093–1097 (1974).
4) Reddy, B. S., Watanabe, K., Weisburger, J. H. and Wynder, E. L. Promoting effect of bile acids in colon carcinogenesis in germfree and conventional F344 rats. Cancer Res., 37, 3238–3242 (1977).
5) Sarwal, A. N., Cohen, B. I., Raicht, R. F., Takahashi, M. and Fazzini, E. Effect of dietary administration of chenodeoxycholic acid on N-methyl-N-nitrosourea-induced colon cancer in rats. Biochim. Biophys. Acta, 574, 423–432 (1979).
6) Cohen, B. I., Raicht, R. F., Deschner, E. E., Takahashi, M., Sarwal, A. N. and Fazzini, E. Effect of cholic acid feeding on N-methyl-N-nitrosourea-induced colon tumors and cell kinetics in rats. J. Natl. Cancer Inst., 64, 573–578 (1980).
7) Czygan, P., Seitz, H., Stiehl, W. A., Raedsch, R. and Kommerrell, B. Chenodeoxycholic acid but not ursodeoxycholic acid enhances colonic carcinogenesis in rats. In "Bile Acid and Cholesterol in Health and Disease," ed. G. Paumgartner, A. Stiehl and G. Gerok, pp. 393–395 (1983).
8) Earnest, D. L., Holubec, H., Wali, R. K., Jolley, C. S., Bissonnette, M., Bhattacharyya, A. K., Roy, H., Khare, S. and Brasitus, T. A. Chemoprevention of azoxymethane-induced colonic carcinogenesis by supplemental dietary ursodeoxycholic acid. Cancer Res., 54, 5071–5074 (1994).
9) Seraj, M. J., Umemoto, A., Kajikawa, A., Mimura, S., Kinouchi, T., Ohnishi, Y. and Monden, Y. Effects of dietary bile acids on formation of azoxymethane-induced aberrant crypt foci in F344 rats. Cancer Lett., 15, 97–103 (1997).
10) Sakakura, H., Suzuki, M., Kimura, N., Takeda, H., Nagata, S. and Maeda, M. Simultaneous determination of bile acids in rat bile and serum by high-performance liquid chromatography. J. Chromatogr., 621, 123–131 (1993).
11) Koutsos, K. L., Shiff, S. J. and Rigas, B. The effect of ursodeoxycholic and lithocholic acid on cell cycle and apoptosis in human colon adenocarcinoma cells. Gastroenterology, 108, A492 (1995).
12) Garreans, H., Bernstein, H., Bernstein, C., Sampliner, R. and Payne, C. Reduced bile acid-induced apoptosis in "normal" colorectal mucosa: a potential biological marker for cancer risk. Cancer Res., 56, 1480–1483 (1996).
13) Haged, A., Elder, D. J. E., Hicks, D. J. and Paraskava, C. Apoptosis in colorectal tumor cells: induction by the short chain fatty acids butyrate, propionate and acetate and by the bile acid deoxycholate. Int. J. Cancer, 60, 400–406 (1995).
14) Marchetti, M. C., Migliorati, G., Moraca, R., Riccardi, C.,
Ursodeoxycholate Prevents Rat Colon Tumors

Nicoletti, I., Fabiani, R., Mastrandrea, V. and Morozzi, G. Possible mechanisms involved in apoptosis of colon tumor cell lines induced by deoxycholic acid, short-chain fatty acids, and their mixtures. *Nutr. Cancer*, **28**, 74–80 (1997).

15) Peiffer, L. P., Peters, D. J. and McGarrity, T. J. Differential effects of deoxycholic acid on proliferation of neoplastic and differentiated colonocytes *in vitro*. *Digest. Dis. Sci.*, **42**, 2234–2240 (1997).

16) Wali, R. K., Frawley, B. P., Jr., Hartmann, S., Roy, H. K., Khare, S., Scaglione-Scell, B. A., Earnest, D. L., Sitrin, M. D., Brasitus, T. A. and Bissonnette, M. Mechanism of action of chemopreventive ursodeoxycholate in the azoxymethane model of rat colonic carcinogenesis: potential roles of protein kinase C-α, -βII, and -ζ. *Cancer Res.*, **55**, 5257–5264 (1995).

17) Narisawa, T. An overview on chemoprevention of colorectal cancer. *J. Jpn. Surg. Soc.*, **99**, 362–367 (1998) (in Japanese).

18) Suh, H., Jung, E. J., Kim, T. H., Lee, H. Y., Park, Y. H. and Kim, K. W. Anti-angiogenic activity of ursodeoxycholic acid and its derivatives. *Cancer Lett.*, **113**, 117–122 (1997).

19) Weisburger, J. H., Reddy, B. S., Barnes, W. S. and Wynder, E. L. Bile acids, but not neutral sterols, are tumor promoters in the colon in man and in rodents. *Environ. Health Perspect.*, **50**, 101–107 (1983).

20) Hill, M. J. Bile acids in colorectal carcinogenesis. In “Gastrointestinal Cancer: Endogenous Factors,” ed. W. R. Bruce, P. Correa, M. Lipkin, S. R. Tannenbaum and T. D. Wilkins, pp. 365–380 (1981). Cold Spring Harbor Laboratory, Long Island, NY.